Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company is headquartered in The Woodlands, Texas and currently employs 87 full-time employees. The company went IPO on 2000-04-07. The firm is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its pipeline includes Sotagliflozin, LX9211, and LX2761. Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes, heart failure and chronic kidney disease. LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The firm is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. LX2761 is an orally-delivered small molecule compound that is designed to inhibit sodium-glucose cotransporter 1 (SGLT1) locally in the gastrointestinal tract without any inhibition of sodium-glucose cotransporter 2 (SGLT2) in the kidney.
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company is headquartered in The Woodlands, Texas and currently employs 87 full-time employees. The company went IPO on 2000-04-07. The firm is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its pipeline includes Sotagliflozin, LX9211, and LX2761. Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes, heart failure and chronic kidney disease. LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The firm is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. LX2761 is an orally-delivered small molecule compound that is designed to inhibit sodium-glucose cotransporter 1 (SGLT1) locally in the gastrointestinal tract without any inhibition of sodium-glucose cotransporter 2 (SGLT2) in the kidney.
Revenue Surge: Lexicon reported Q3 2025 revenue of $14.2 million, a significant jump from $1.8 million in Q3 2024, mainly due to $13.2 million in licensing revenue from Novo Nordisk.
Cost Discipline: Operating expenses dropped sharply, with SG&A down to $7.6 million from $39.6 million and R&D at $18.8 million, reflecting strategic repositioning and efficiency measures.
Pilavapadin Progress: Phase II data for pilavapadin in neuropathic pain met key objectives, with an end-of-Phase II FDA meeting scheduled by year-end and active partnership discussions underway.
Sotagliflozin Pipeline Momentum: All SONATA Phase III trial sites for HCM are now active, and enrollment is accelerating; new data presentations are expected soon.
Regulatory Updates: Lexicon expects FDA feedback on Zynquista for type 1 diabetes by year-end, targeting a resubmission in early 2026.
Guidance Maintained: Full-year 2025 guidance for operating expenses remains unchanged at $105–115 million.
Strategic Partnerships: Ongoing collaborations with Viatris and Novo Nordisk continue to advance key assets and could result in near-term milestone payments.
